Page 57 - Clinical Development News Today

Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer Updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose...

Virtual research organization, ObvioHealth, has just announced the launch of its application programming interface (API) which it says is tailored specifically for digital therapeutics (DTx) clinical trials.

/PRNewswire/ -- The "LNP023 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report provides...

Adults and children in the US with congenital thrombotic thrombocytopenic purpura (cTTP) can now access Adzynma for prophylactic and on-demand treatment.

OSP had a great conversation with Mike Connell, chief operating officer, at Enthought. The discussion centered around aritificial intelligence (AI) which have been the buzzwords in pharma and a number of other industries for at least the last year.

Today, world-leading generative artificial intelligence (AI) company for life sciences, Yseop, is celebrating its involvement in more than 150 clinical trials with pharma giants around the world.

/PRNewswire/ -- The "Itacitinib Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report...

PRESS RELEASE – INSIDE INFORMATION Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt. Mont-Saint-Guibert, Belgium, December 6, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing ...

A significantly greater improvement in people with depression was achieved after they were given ALT-300, an adjunctive treatment, during a phase 2a study.

Zizi Uzezi Imatorbhebhe has more than 30 years of experience in the biopharmaceutical, healthcare and clinical research industries.